IP Library Granted Patent US 10,655,184
Granted Patent B2
US 10,655,184 · App. 15/491,399 · Granted May 19, 2020

Methods and compositions involving miR-135b for distinguishing pancreatic cancer from benign pancreatic disease

Inventors: Alex Adai (Austin, TX); Anna Szafranska-Schwarzbach (Austin, TX); Bernard Andruss (Austin, TX); Stephan Albrecht Hahn (Bochum, DE)
Assignee: INTERPACE DIAGNOSTICS, LLC
C12Q1/6886C12Q1/6844C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,655,184
App. No.
15/491,399
Granted
May 19, 2020
Kind
B2
Abstract

Provided are methods and compositions for identifying a miRNA profile for a particular condition, such as pancreatic disease, and using the profile in assessing the condition of a patient.

Claims (9)

1. A method of producing amplified, labeled miRNA molecules from a pancreatic sample from a subject, the method comprising:

contacting the pancreatic sample from the subject with primers specific for a group of microRNAs consisting of up to 11 different labeled miRNAs that include at least miR-135b and at least 4 of the following miRNAs: miR148a, miR-130b, miR-196a, miR-24, miR-375, and miR-96,

wherein miR-217 is not one of the up to 11 different miRNAs; and

reacting the sample with the primers under conditions to amplify the labeled microRNA molecules using polymerase chain reaction to produce the amplified, labeled miRNA molecules.

2. The method of claim 1 , wherein the group of microRNAs consists of up to 7 different labeled miRNA molecules.

3. The method of claim 1 , wherein the pancreatic sample is a biopsy.

4. The method of claim 3 , wherein the biopsy is surgical resection or a fine needle aspirate.

5. The method of claim 1 , further comprising obtaining a sample from the subject.

6. The method of claim 1 , further comprising labeling the miRNA molecules from a pancreatic sample prior to reacting the sample with the primers.

Assignments (8)
SECURITY INTEREST Recorded Nov 2, 2021
From: INTERPACE BIOSCIENCES, INC.; INTERPACE DIAGNOSTICS CORPORATION; INTERPACE DIAGNOSTICS, LLC; INTERPACE PHARMA SOLUTIONS, INC.
To: BROADOAK FUND V, L.P.
Reel/Frame 057988/0110 →
SECURITY INTEREST Recorded Oct 20, 2021
From: INTERPACE DIAGNOSTICS, LLC
To: COMERICA BANK
Reel/Frame 057851/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2018
From: ADAI, ALEX; SZAFRANSKA-SCHWARZBACH, ANNA; ANDRUSS, BERNARD; HAHN, STEPHAN ALBRECHT
To: ASURAGEN, INC.
Reel/Frame 044522/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2018
From: ASURAGEN, INC.
To: INTERPACE DIAGNOSTICS, LLC
Reel/Frame 044522/0367 →
RELEASE OF SECURITY INTEREST Recorded Jun 16, 2017
From: HUDSON BAY MASTER FUND LTD
To: INTERPACE DIAGNOSTICS CORPORATION
Reel/Frame 042858/0971 →
RELEASE OF SECURITY INTEREST Recorded Jun 16, 2017
From: HUDSON BAY MASTER FUND LTD
To: INTERPACE DIAGNOSTICS GROUP, INC.; INTERPACE BIOPHARMA, LLC; INTERPACE DIAGNOSTICS, LLC; INTERPACE DIAGNOSTICS LAB, INC.; INTERPACE DIAGNOSTICS CORPORATION
Reel/Frame 042840/0860 →
RELEASE OF SECURITY INTEREST Recorded Jun 16, 2017
From: HUDSON BAY MASTER FUND LTD
To: INTERPACE DIAGNOSTICS GROUP, INC.; INTERPACE DIAGNOSTICS, LLC; INTERPACE DIAGNOSTICS CORPORATION
Reel/Frame 042856/0799 →
RELEASE OF SECURITY INTEREST Recorded Jun 16, 2017
From: HUDSON BAY MASTER FUND LTD
To: INTERPACE DIAGNOSTICS CORPORATION
Reel/Frame 042856/0895 →
Continuity (4)
Continuation 13615066 · Sep 13, 2012
Provisional Application 61536486 · Sep 19, 2011
Provisional Application 61534332 · Sep 13, 2011
Related Publication 20180066316A1 · Mar 8, 2018